Shareholder pressures Capricor; Lilly dives deeper into vaccines
Kaos Capital wants a “governance reset” to alter the Duchenne cell therapy maker’s strategic course. Elsewhere, Bristol Myers furthered efforts to build an “AI-powered” discovery engine.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.